Phase 4
N=132
Adductor Canal Block Versus Femoral Block on Pain and Quadriceps Strength
Anterior Cruciate Ligament Tear · Knee Meniscus Tear
Bottom Line
View on ClinicalTrials.gov: NCT05190120 ↗Enrolled (actual)
132
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Change in Quadriceps Strength Related to the Nerve Block — -0.42; -0.55; -3.19; -0.77 Newtons
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Femoral Nerve Block (Procedure); Adductor Canal Nerve Block (Procedure); preoperative Femoral Nerve Block using 20ml of 0.5% ropivacaine (Drug); Preoperative Adductor canal block with 0.75%% ropivacaine 13.3ml. (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Mar 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Quadriceps Strength Related to the Nerve Block |
-0.42; -0.55; -3.19; -0.77 | — |
| SECONDARY Numerical Pain Score From 0-10 |
4.5; 5; 7; 6.5 | — |
| SECONDARY Duration of Nerve Block |
678; 731; 889; 923 | — |
| SECONDARY Opioid Consumption Reported at mg of Morphine Equivalence |
40; 51.25; 20; 20 | — |
Summary
The purpose of this study is to compare the effects of a femoral nerve block vs. an adductor canal block on pain and quadriceps muscle strength for knee arthroscopy surgery.
Eligibility Criteria
Inclusion Criteria
- American Society of Anesthesia I-III classification,
- Scheduled for arthroscopic knee surgery (meniscal debridement/repair, ACL reconstruction)
Exclusion Criteria
- Age younger than 18 years
- Non-English speaking
- Any contraindication for regional anesthesia, such as allergy to local anesthetics or opioids, -Coagulopaty or severe thrombocytopenia
- Infection at puncture sites
- Pre-existing neuropathy in operative limb
- Need for post-operative nerve function monitoring
- Dementia
- Patient refusal
- High pre-operative opioid requirements
Data sourced from ClinicalTrials.gov (NCT05190120). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.